OUR MISSION

Alma Bio Therapeutics goes one step further in the treatment of autoimmune diseases by using body’ own mechanims to restore the original immune balance, with no overdrive and no immune suppression.

• Aims to resolve inflammation at inflammatory site
• Does not affect normal immune response

• Active only when required

 

• No toxicity observed in preclinical studies

Healthcare Facts

M

>100 million patients worldwide, including over 20 million in Europe

>90 different autoimmune diseases, e.g. juvenile diabetes, rheumatoïd arthritis, IBD, multiple sclerosis

%

the incidence of IBD has risen by 60% over the last 8 years

B€

> €120 billion global annual cost of care

Meet the team

The founders and team behind Alma Biotherapeutics are motivated by the mission to improve the way autoimmune diseases are treated.

Dr. Binah Baum Dr. Binah Baum CEO and co Founder

Dr. Binah Baum

CEO and co Founder

Dr. Binah Baum

A seasoned biopharmaceutical executive and serial entrepreneur, Dr, Baum has participated in the founding of over 30 start ups located in Europe, the US and Israel. To-date, six have had successful exits. Dr. Baum teamed up with Dr. Cohen’s in founding Alma Biotherapeutics in order to apply new knowledge of the mechanisms underlying autoimmune disease to the development of therapeutic interventions for these chronic conditions.

X
Prof. Irun Cohen Prof. Irun Cohen Inventor, Chief Scientific Advisor and co Founder

Prof. Irun Cohen

Inventor, Chief Scientific Advisor and co Founder

Prof. Irun Cohen

Decades of research conducted by Dr. Cohen are the foundation for Alma’s Biotherapeutics drug discovery and development platform. Dr. Cohen is a world leading research immunologist who has received the Robert Koch Prize  and the AESKU Prize for his Life Contribution to Autoimmunity Research. Dr. Cohen remains a Professor Emeritus of Immunology, Weizmann Institute of Science.

X
Dr. Denis Ravel Dr. Denis Ravel Director of Preclinical Development and Regulatory Affairs

Dr. Denis Ravel

Director of Preclinical Development and Regulatory Affairs

Dr. Denis Ravel

Dr. Ravel brings 30 years’ experience as executive who has ushered drugs from concept to to the clinic for bio-pharmaceutical companies including Servier, Genset/MerckSerono, and Diatos.

X
Dr. Pierre A. Morgon Dr. Pierre A. Morgon Non Executive Director

Dr. Pierre A. Morgon

Non Executive Director

Dr. Pierre A. Morgon
X

“Immunity is a balancing act. Our approach attempts to tilt the balance away from the harmful inflammation associated with autoimmune diseases and toward healing.”  World Leading Research Immunologist, Irun Cohen, Professor Emeritus of Immunology

Our Technology

Social Media

Stay up-to-date with our latest company news, and life blogsentries via your favourite social network services.

Get in touch

 


 

LEGAL NOTICE